2023-05-01 2024-04-30 false Capium Accounts Production 1.1 11312266 2023-05-01 2024-04-30 11312266 bus:AbridgedAccounts 2023-05-01 2024-04-30 11312266 bus:FRS102 2023-05-01 2024-04-30 11312266 bus:AuditExemptWithAccountantsReport 2023-05-01 2024-04-30 11312266 bus:SmallCompaniesRegimeForAccounts 2023-05-01 2024-04-30 11312266 bus:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 11312266 2023-05-01 2024-04-30 11312266 2024-04-30 11312266 bus:RegisteredOffice 2023-05-01 2024-04-30 11312266 core:WithinOneYear 2024-04-30 11312266 core:AfterOneYear 2024-04-30 11312266 1 2023-05-01 2024-04-30 11312266 bus:Director1 2023-05-01 2024-04-30 11312266 bus:Director1 2024-04-30 11312266 bus:Director1 2022-05-01 2023-04-30 11312266 2022-05-01 11312266 bus:LeadAgentIfApplicable 2023-05-01 2024-04-30 11312266 2022-05-01 2023-04-30 11312266 2023-04-30 11312266 core:WithinOneYear 2023-04-30 11312266 core:AfterOneYear 2023-04-30 11312266 bus:EntityAccountantsOrAuditors 2022-05-01 2023-04-30 11312266 bus:OrdinaryShareClass1 2023-05-01 2024-04-30 11312266 bus:OrdinaryShareClass1 2024-04-30 11312266 bus:OrdinaryShareClass1 2022-05-01 2023-04-30 11312266 bus:OrdinaryShareClass1 2023-04-30 11312266 core:PlantMachinery 2023-05-01 2024-04-30 11312266 core:PlantMachinery 2024-04-30 11312266 core:PlantMachinery 2023-04-30 11312266 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-04-30 11312266 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-04-30 11312266 core:CostValuation core:Non-currentFinancialInstruments 2024-04-30 11312266 core:CostValuation core:Non-currentFinancialInstruments 2023-04-30 11312266 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-04-30 11312266 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-04-30 11312266 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-04-30 11312266 core:Non-currentFinancialInstruments 2024-04-30 11312266 core:Non-currentFinancialInstruments 2023-04-30 11312266 core:ShareCapital 2024-04-30 11312266 core:ShareCapital 2023-04-30 11312266 core:RetainedEarningsAccumulatedLosses 2024-04-30 11312266 core:RetainedEarningsAccumulatedLosses 2023-04-30 11312266 dpl:Item1 2023-05-01 11312266 dpl:Item1 2024-04-30 11312266 dpl:Item1 2022-05-01 11312266 dpl:Item1 2023-04-30 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 11312266
England and Wales

 

 

 

ANGEL & LOCKHART (PHARMA) LTD


Abridged Accounts
 


Period of accounts

Start date: 01 May 2023

End date: 30 April 2024
Accountant’s report
You consider that the company is exempt from an audit for the year ended 30 April 2024 . You have acknowledged, on the balance sheet, your responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These responsibilities include preparing accounts that give a true and fair view of the state of affairs of the company at the end of the financial year and of its profit or loss for the financial year.
In accordance with your instructions, we have prepared the accounts which comprise the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the accounting records of the company and on the basis of information and explanations you have given to us.
We have not carried out an audit or any other review, and consequently we do not express any opinion on these accounts.
Mayfair Associates London Ltd
30 April 2024



....................................................

Mayfair Associates London Ltd

69 Banstead Road
Carshalton
SM5 3NP
31 January 2025
1
 
 
Notes
 
2024
£
  2023
£
Fixed assets      
Tangible fixed assets 3 118    235 
118    235 
Current assets      
Debtors 10,000    1,838 
Cash at bank and in hand 3    898 
10,003    2,736 
Creditors: amount falling due within one year (4,373)   (2,721)
Net current assets 5,630    15 
 
Total assets less current liabilities 5,748    250 
Net assets 5,748    250 
 

Capital and reserves
     
Called up share capital 4 1    1 
Profit and loss account 5,747    249 
Shareholders' funds 5,748    250 
 


For the year ended 30 April 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the director on 31 January 2025 and were signed by:


-------------------------------
Barry Joseph Davis
Director
2
General Information
Angel & Lockhart (Pharma) Ltd is a private company, limited by shares, registered in England and Wales, registration number 11312266, registration address 43 Berkeley Square , Mayfair , London, W1J 5AP.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Going concern basis
The directors believe that the company is experiencing good levels of sales growth and profitability, and that it is well placed to manage its business risks successfully. Accordingly, they have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Plant and Machinery 20% Straight Line
2.

Average number of employees

Average number of employees during the year was 0 (2023 : 0).
3.

Tangible fixed assets

Cost or valuation Plant and Machinery   Total
  £   £
At 01 May 2023 586    586 
Additions  
Disposals  
At 30 April 2024 586    586 
Depreciation
At 01 May 2023 351    351 
Charge for year 117    117 
On disposals  
At 30 April 2024 468    468 
Net book values
Closing balance as at 30 April 2024 118    118 
Opening balance as at 01 May 2023 235    235 


4.

Share Capital

Allotted, called up and fully paid
2024
£
  2023
£
1 Ordinary - Class1 share of £1.00 each  
 

3